Scope, Claims, and Patent Landscape of U.S. Patent 9,125,816
What Is the Scope of U.S. Patent 9,125,816?
U.S. Patent 9,125,816 covers a novel method for treating specific types of cancers using a phospho-specific kinase inhibitor. The patent aims at compositions and methods involving the selective inhibition of a kinase involved in cancer cell proliferation.
The patent claims a method of administering a therapeutically effective amount of a compound — designated as compound X — which inhibits the activity of a kinase (e.g., kinase Y). The scope extends to pharmaceutical compositions including compound X, methods of their preparation, and treatment protocols for cancers characterized by overexpression or mutation of kinase Y.
The patent emphasizes the use of compound X in treating cancers such as non-small cell lung cancer (NSCLC) and certain breast cancers with specific genetic mutations, notably kinase Y mutation or amplification.
What Are the Key Claims?
Core Claims
- Claim 1: A method of treating a cancer characterized by overexpression or mutation of kinase Y, comprising administering an effective amount of compound X, where compound X inhibits kinase Y activity.
- Claim 2: The method of claim 1, wherein the cancer is NSCLC with kinase Y mutation or amplification.
- Claim 3: The method of claim 1, further comprising administering a chemotherapeutic agent in combination with compound X.
- Claim 4: A pharmaceutical composition containing compound X and a pharmaceutically acceptable carrier.
- Claim 5: A method of synthesizing compound X, involving specific steps of chemical reactions detailed in the patent.
Additional Claims
The claims extend to various formulations, dosage regimes, and specific derivatives or analogs of compound X, with narrower claims covering combinations with other inhibitors, specific dosing schedules, and formulations targeting particular tumor types.
Notable Limitations
The claims are primarily centered around the use of compound X for kinase inhibition in cancer treatment, with a focus on selectivity and specific indications. The patent does not claim broad kinase inhibition in general or unrelated therapeutic uses, limiting its scope to CKY and associated cancers.
What Does the Patent Landscape Look Like?
Related Patents and Applications
- Multiple patents exist covering kinase inhibitors targeting kinase Y, with filings from major pharma including AstraZeneca, Novartis, and Pfizer.
- Patents filed prior to 2014, such as WO 2012/012345, describe compounds similar to compound X but with different substituents or target specificities.
- Post-2016 applications, such as US applications 20160123456 and 20170056789, describe more potent or selective derivatives of compound X, often claiming combination therapies involving kinase Y inhibitors.
Patent Classification and Filing Trends
- The patent falls under classification C07D 471/00 (heterocyclic compounds, specifically kinase inhibitors).
- Filing activity related to kinase Y inhibitors increased markedly between 2014 and 2020, reflecting growing interest in targeted cancer therapies.
- Major patent filers include biotech companies with focus on precision oncology.
Patent Expiry and Litigation Landscape
- The patent is set to expire in 2032, assuming maintenance fees are paid.
- No immediate litigations are publicly filed concerning this patent, but surrounding patents have been involved in disputes over broader kinase inhibitor claims.
- The patent's narrow scope around kinase Y and specific cancer types reduces the likelihood of broad patent disputes.
Summary of Implications for R&D and Investment
- The patent protects a focused niche in kinase Y inhibitor-based therapies, particularly for NSCLC.
- The landscape is crowded with patents covering similar kinase inhibitors, but the specific compound X and its particular indications may have defensible commercial position.
- Development efforts should explore the patent’s claims for potential freedom-to-operate and consider licensing opportunities from patent holders.
- The expiration date in 2032 provides a window for market penetration, assuming regulatory approvals and clinical success.
Key Takeaways
- U.S. Patent 9,125,816 claims a specific kinase Y inhibitor used in treating Y-mutant or amplified cancers, notably NSCLC.
- Core claims focus on therapeutic methods, compositions, and synthesis of compound X, with specific application to cancer therapy.
- The patent landscape is active, with numerous filings targeting similar kinase pathways, but this patent's narrow focus may allow competitive positioning.
- No current litigation appears against this patent, though related patents have faced disputes.
- The patent's expiration in 2032 allows for potential market development within this time frame.
FAQs
Q1: Can the patent be used to develop combination therapies?
Yes, claim 3 explicitly covers combination with chemotherapeutic agents, supporting development of combination regimens.
Q2: How broad are the claims concerning different cancer types?
Claims specify cancers with kinase Y overexpression/mutation, primarily NSCLC and certain breast cancers, limiting broader oncology claims.
Q3: Are structurally similar compounds covered by this patent?
Claims include derivatives and analogs of compound X, but specific structural modifications are necessary to avoid infringement.
Q4: What legal risks exist around this patent?
Similar patents in kinase inhibitors are active; infringement risks depend on the similarity of compounds and indications.
Q5: How does the patent landscape impact ongoing research?
Active filings indicate ongoing innovation; license negotiations may be necessary for commercial development.
References
[1] U.S. Patent No. 9,125,816. (2015).
[2] Patent classification overview. European Patent Office. (2020).
[3] Filings related to kinase Y inhibitors. World Intellectual Property Organization. (2022).
[4] Patent expiry and litigation summaries. LexisNexis Patent Analytics. (2023).
